GLENMARK PHARMACEUTICALS LTD. - Clarifies on News item

Download	< Back
29 Oct 2015
With reference to news reported on CNBC TV18 on October 29, 2015 - "Setback For Glenmark: 'Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule'.", Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of Clarification is enclosed.
View all announcements for GLENMARK PHARMACEUTICALS LTD.	Source: BSE India

ALL MONEYWIZ PAGES

Stocks	Mutual Funds		Investment tracking
A-Z Gainers - Daily \| Weekly \| Monthly Losers - Daily \| Weekly \| Monthly Group-wise listing IPO \| Top IPOs Recent IPOs \| IPO News Similar Price band Most traded - By volumes Top 100 - By market capitalisation Latest Company Results Management Speaks Market News	Top 25 schemes High-risk, High-returns Medium-risk, Medium-returns Low-risk, Low-returns Gilt Funds Funds of Funds Special Funds Liquid Funds Dynamic Asset Allocation NFOs MF Selector	Equity - ELSS Equity - Index Funds Equity - Sector Funds Equity - Balance Fund Equity - Diversified Fund MF News Budget 2024	My Portfolio My Watch List If You Had Invested... Global Indicators Forex Converter Market Indices Sectoral Indices World Indices Market Astrology Advertise with us